Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma : A Propensity Score Matching Study
BACKGROUND/AIMS: This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib vs hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma.
METHODOLOGY: Forty-seven patients treated with sorafenib (sorafenib group) and 77 patients treated with HAIC (HAIC group) were investigated retrospectively using propensity score matching (PSM) to minimize selection bias. The cumulative survival rate was investigated before and after PSM in each of the sorafenib and HAIC groups. The cumulative survival rate was compared between the sorafenib and HAIC groups, and among the TNM stage by the Liver Cancer Study Group of Japan (LCSGJ TNM stage).
RESULTS: No significant difference was noted in overall survival (OS) between the sorafenib and HAIC groups regardless of before or after PSM. On comparison of the cumulative survival rate between the groups by the same LCSGJ TNM stage, significant prolongation of OS was noted in stage IVB only in the sorafenib group (p = 0.032) after PSM.
CONCLUSIONS: It may be better to actively introduce sorafenib for stage IVB, i.e., patients with extrahepatic metastasis.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Hepato-gastroenterology - 61(2014), 132 vom: 12. Juni, Seite 885-91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shiozawa, Kazue [VerfasserIn] |
|---|
| Themen: |
25X51I8RD4 |
|---|
| Anmerkungen: |
Date Completed 12.08.2015 Date Revised 30.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM250722909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250722909 | ||
| 003 | DE-627 | ||
| 005 | 20231224160430.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0835.xml |
| 035 | |a (DE-627)NLM250722909 | ||
| 035 | |a (NLM)26158136 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shiozawa, Kazue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma |b A Propensity Score Matching Study |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2015 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib vs hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma | ||
| 520 | |a METHODOLOGY: Forty-seven patients treated with sorafenib (sorafenib group) and 77 patients treated with HAIC (HAIC group) were investigated retrospectively using propensity score matching (PSM) to minimize selection bias. The cumulative survival rate was investigated before and after PSM in each of the sorafenib and HAIC groups. The cumulative survival rate was compared between the sorafenib and HAIC groups, and among the TNM stage by the Liver Cancer Study Group of Japan (LCSGJ TNM stage) | ||
| 520 | |a RESULTS: No significant difference was noted in overall survival (OS) between the sorafenib and HAIC groups regardless of before or after PSM. On comparison of the cumulative survival rate between the groups by the same LCSGJ TNM stage, significant prolongation of OS was noted in stage IVB only in the sorafenib group (p = 0.032) after PSM | ||
| 520 | |a CONCLUSIONS: It may be better to actively introduce sorafenib for stage IVB, i.e., patients with extrahepatic metastasis | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a Sorafenib |2 NLM | |
| 650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
| 700 | 1 | |a Watanabe, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Ikehara, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Kogame, Michio |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Okano, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Hidenari |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Makino, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Igarashi, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Sumino, Yasukiyo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepato-gastroenterology |d 1993 |g 61(2014), 132 vom: 12. Juni, Seite 885-91 |w (DE-627)NLM012633151 |x 0172-6390 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2014 |g number:132 |g day:12 |g month:06 |g pages:885-91 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2014 |e 132 |b 12 |c 06 |h 885-91 | ||